SANTA ANA, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) — NKGen Biotech, Inc., a biotechnology firm harnessing the energy of the physique’s immune system by way of the improvement of pure killer (NK) cell therapies, at the moment introduced a collaboration with the Parkinson’s Foundation that can concentrate on methods to assist speed up NKGen’s scientific program utilizing its novel autologous NK cell remedy (SNK01) for the remedy of superior Parkinson’s illness (PD) by way of its community of scientific companions and donors.
“Recent research has shown that NK cells can help remove alpha-synuclein proteins, reduce autoreactive T cell generated inflammation, and remove damaged neurons. We believe our non-genetically modified, enhanced, and expanded NK cells (SNK01) can provide an entirely new therapeutic approach to Parkinson’s disease which currently lacks effective disease modifying modalities,” stated Paul Y. Song, MD, Vice Chairman of NKGen Biotech. “We are very impressed with the Parkinson’s Foundation’s holistic approach towards improving patient care and supporting cutting-edge research. We are confident that they will be a great partner for us as we bring our treatment for Parkinson’s disease to the clinic in 2023.”
“The Parkinson’s Foundation has a strong commitment to identify and accelerate promising scientific breakthroughs in the treatment of PD,” stated John L. Lehr, President and CEO of the Parkinson’s Foundation. “We are looking to support novel innovative approaches in PD, and we are attracted to NKGen’s unwavering commitment to bring their NK cell therapy to the clinic very quickly.”
About NKGen Biotech
NKGen Biotech, Inc. is a clinical-stage biotechnology firm targeted on the improvement and commercialization of progressive autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. Leveraging our proprietary cell growth and activation know-how and progressive cell manufacturing experience, we’ve the skill to infinitely broaden pure killer cells whereas considerably enhancing cytotoxicity throughout our peripheral blood-derived merchandise. NKGen Biotech’s lead product candidate, SNK01, is at the moment in scientific trials for the remedy of superior refractory strong tumors each as a monotherapy and together with different brokers, together with checkpoint inhibitors and cell engagers. NKGen Biotech is dedicated to the imaginative and prescient of executing on our scientific methods with the aim of commercializing our NK cell therapies to assist save and maintain sufferers’ lives worldwide. The firm and its commercially licensed cGMP facility are headquartered in Santa Ana, California, USA. For extra data, please go to www.nkgenbiotech.com.
About the Parkinson’s Foundation
The Parkinson’s Foundation makes life higher for folks with Parkinson’s illness by bettering care and advancing analysis towards a treatment. In every thing we do, we construct on the power, expertise, and keenness of our world Parkinson’s group. Since 1957, the Parkinson’s Foundation has invested greater than $400 million in Parkinson’s analysis and scientific care. Connect with us on Parkinson.org, Facebook, Twitter, Instagram or name (800)4PD-INFO (473-4636).
Contact:
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications
949-396-6830
[email protected]
